Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bimatoprost. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR known ✓ | P43088 | 8/20 | 0.80 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 1/20 | 1.00 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.80 |
| ▸ | CA2 | P00918 | 1/20 | 0.64 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.63 |
| ▸ | MGLL | Q99685 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.59 |
| ▸ | SLCO2A1 | Q92959 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.59 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.57 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bimatoprost SCHEMBL1286359 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL12087441 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL10015911 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL399000 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL24425 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL11977332 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL13187412 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL20434484 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL22364345 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 | |
| Bimatoprost SCHEMBL12076308 | 1.00 | ABCB11 (1.00) | ABCB11AKR1C3PTGFRPTGER3CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025226840-A1 | INTRAOCULAR DRUG DELIVERY DEVICES, SYSTEMS, AND METHODS OF USE | SpyGlass Pharma, Inc. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20250312191-A1 | INTRAOCULAR DRUG DELIVERY DEVICES, SYSTEMS, AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2025-10-09 | — | — | US | disclosed |
| EP-4558093-A2 | INTRAOCULAR DRUG DELIVERY SYSTEMS AND METHODS OF USE | Spyglass Pharma, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20250152414-A1 | INTRAOCULAR DRUG DELIVERY SYSTEMS AND METHODS OF USE | SpyGlass Pharma, Inc. | 2025-05-15 | — | — | US | disclosed |
| US-12285357-B2 | Intraocular drug delivery systems and methods of use | SpyGlass Pharma, Inc. (US) | 2025-04-29 | — | — | US | disclosed |
| US-12193972-B2 | Intraocular drug delivery systems and methods of use | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2025-01-14 | — | — | US | disclosed |
| US-20240207287-A1 | POLYMERIC IMPLANTS | ALLERGAN INC (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2024020505-A2 | INTRAOCULAR DRUG DELIVERY SYSTEMS AND METHODS OF USE | SpyGlass Pharma, Inc. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20240024092-A1 | INTRAOCULAR DRUG DELIVERY SYSTEMS AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2024-01-25 | — | — | US | disclosed |
| US-20240024093-A1 | INTRAOCULAR DRUG DELIVERY SYSTEMS AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2024-01-25 | — | — | US | disclosed |
| US-8772544-B2 | Process for the production of bimatoprost | SANDOZ AG (CH) | 2014-07-08 | — | — | US | disclosed |
| US-20140135503-A1 | NOVEL PROCESSES FOR THE PREPARATION OF PROSTAGLANDIN AMIDES | CHINOIN Zrt. (HU) | 2014-05-15 | — | — | US | disclosed |
| WO-2012011128-A1 | PREPARATION OF PROSTAGLANDIN DERIVATIVES | APTUIT LAURUS PRIVATE LIMITED (IN) | 2012-01-26 | — | — | WO | disclosed |
| US-20110288179-A1 | BIMATOPROST CRYSTALLINE FORM I | FINETECH PHARMACEUTICAL LTD. (IL) | 2011-11-24 | — | — | US | disclosed |
| US-20110178340-A1 | IMPROVED PROCESS FOR THE PRODUCTION OF BIMATOPROST | SANDOZ AG (CH) | 2011-07-21 | — | — | US | disclosed |
| US-20110178340-A1 | IMPROVED PROCESS FOR THE PRODUCTION OF BIMATOPROST | SANDOZ AG (CH) | 2011-07-21 | — | — | US | disclosed |
| US-7947740-B2 | Bimatoprost crystalline form I | FINETECH PHARMACEUTICAL LTD (IL) | 2011-05-24 | — | — | US | disclosed |
| EP-2135860-A1 | Improved process for the production of bimatoprost | Sandoz AG (CH) | 2009-12-23 | — | — | EP | disclosed |
| WO-2009153206-A2 | Improved Process for the Production of Bimatoprost | SANDOZ AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| US-20090163596-A1 | Bimatoprost crystalline form I | FINETECH PHARMACEUTICAL LTD. (IL) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178340-A1 | IMPROVED PROCESS FOR THE PRODUCTION OF BIMATOPROST | AVPR2, PTGIR, ADH1A | PTGFR 19/4885ABCB11 442/4885AKR1C3 45/4885 |
| US-20140135503-A1 | NOVEL PROCESSES FOR THE PREPARATION OF PROSTAGLANDIN AMIDES | PTGES, ALOX5, PTGER2 | PTGFR 25/4885ABCB11 3418/4885AKR1C3 130/4885 |
| US-20090163596-A1 | Bimatoprost crystalline form I | PTGER1, BBC3, CYP2A7 | PTGFR 28/4885ABCB11 465/4885AKR1C3 171/4885 |
| US-20240207287-A1 | POLYMERIC IMPLANTS | PDE6C, PDE6A, PHOSPHO1 | PTGFR 247/4885ABCB11 781/4885AKR1C3 2627/4885 |
| US-20110288179-A1 | BIMATOPROST CRYSTALLINE FORM I | PTGER1, BBC3, CYP2A7 | PTGFR 28/4885ABCB11 465/4885AKR1C3 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.